Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Jcr Pharmaceuticals Co. Ltd. has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are assigned to 3 distinct examiners and 3 distinct art units. This distribution shows that each of the 3 pending office actions is being handled by a unique examiner in a separate technical division.
The busiest examiner is WEN, SHARON X, who is responsible for 1 busiest examiner pending office action. With 3 pending office actions and 3 distinct examiners, the company's prosecution is spread across multiple individuals at the USPTO. This lack of concentration means that the company must navigate the specific requirements of 3 distinct art units simultaneously. The 1 busiest examiner pending office action is one of the 3 pending office actions for the company.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (67%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WEN, SHARON X | 1 | 56.8% | +32.6% |
| GABEL, GAILENE | 1 | 75.6% | +44.7% |
| ABEYRATNE-PERERA, HASHANTHI KOMITIGE | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18280771 | Method for Producing Antibody-Lysosomal Enzyme Fusion Protein | GABEL, GAILENE | — |
| 18271839 | Nucleic Acid Molecule Containing Incorporated Gene Encoding Fused Protein of Ligand and Protein Having Physiological Activity | ABEYRATNE-PERERA, HASHANTHI KOMITIGE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18290001 | Pharmaceutical Composition for Treatment of Mucopolysaccharidosis Type 1 | WEN, SHARON X | — |
| 18280771 | Method for Producing Antibody-Lysosomal Enzyme Fusion Protein | GABEL, GAILENE | — |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| 1678 | 1 |
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18290001 | Pharmaceutical Composition for Treatment of Mucopolysaccharidosis Type 1 | WEN, SHARON X | 1641 | §103DP | Final Rejection | — | Pending | Nov 08, 2023 |
| 18280771 | Method for Producing Antibody-Lysosomal Enzyme Fusion Protein | GABEL, GAILENE | 1678 | §103§112 | Non-Final OA | — | Pending | Sep 07, 2023 |
| 18271839 | Nucleic Acid Molecule Containing Incorporated Gene Encoding Fused Protein of Ligand and Protein Having Physiological Activity | ABEYRATNE-PERERA, HASHANTHI KOMITIGE | 1632 | §103§112DP | Non-Final OA | — | Pending | Jul 11, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialJcr Pharmaceuticals Co. Ltd. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Sharon X Wen has the most, with 1 of Jcr Pharmaceuticals Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
